Business

How This Business Actually Works

Convatec is a chronic-care consumables company, not a capital equipment cycle story: over 90% of revenue comes from recurring products used by patients with long-term conditions. The stock turns on whether that steady base can compound at mid- to high-single-digit organic growth while adjusted operating margin moves from 22.3% toward the mid-20s. The market is most likely to overestimate the durability of any single product spike, such as InnovaMatrix, and underestimate the value of steady share gains in ostomy, continence, and infusion.

Revenue Mix: The group is balanced across four chronic-care categories, but the incremental growth engine in 2025 was Infusion Care while the visible wobble came from one small reimbursement-sensitive wound product.

Economic Engine: Demand starts with chronic use, but profit is created when new products pull through existing clinical relationships and automated plants.

The cost structure is attractive but not effortless: reported gross margin was 56.2% in FY2025, adjusted gross margin was 60.7%, and adjusted operating expense fell to 38.4% of revenue as G&A leverage improved. The bottlenecks are reimbursement, clinical evidence, quality systems, and capacity timing; scale helps only if those gates are managed well.

The Playing Field

The closest public yardstick is Coloplast, because it shows what a focused chronic-care franchise can earn when launches, service, and reimbursement execution are all working.

Peer Table: Convatec is no longer the laggard it was after IPO, but the best peer still earns a meaningfully higher margin.

Peer Positioning: The premium peer set rewards focused chronic-care growth and margins, not generic medical-device scale.

The peer set says the moat is not "being in medical devices." The advantage comes from intimate chronic categories where comfort, service, payor access, and clinician trust make switching slow; the weakness is that Convatec still needs to prove Coloplast-like execution without letting product launches, quality remediation, or reimbursement surprises consume the margin runway.

Is This Business Cyclical?

This is defensive on demand but cyclical in reimbursement, input costs, working capital, and launch execution.

Cycle Track: Growth did not collapse through recent stress periods, but free cash flow and reported profit can move around when inflation, capex, or reimbursement hits.

A recession should not break demand for ostomy pouches, catheters, wound dressings, or infusion sets. The real downcycle is a payor or regulator saying "same product, lower economics," or a capacity/quality issue stopping Convatec from serving demand when launches are working.

The Metrics That Actually Matter

The useful metrics are the ones that link patient recurrence to incremental profit, not headline reported EPS alone.

Metric Scorecard: The thesis is strongest where growth, margin, and cash conversion rise together without increasing reimbursement or quality risk.

Do not anchor on reported EPS alone: FY2025 reported operating margin was 13.0%, while adjusted operating margin was 22.3% because amortization, impairment, and other adjustments still matter. The investor question is whether the adjusted number is becoming cleaner cash earnings or just a nicer version of a messier business.

What Is This Business Worth?

Value is mostly determined by cash earnings power plus the reinvestment runway in chronic-care consumables.

Convatec is best valued as one economic engine, not a sum-of-the-parts: the categories share clinical access, polymers, adhesives, manufacturing capability, market access, and back-office scale. A premium multiple requires evidence that the 6-8% growth target is not just a launch-cycle peak and that the margin bridge to the mid-20s survives reinvestment.

Valuation Lens: The stock is cheap only if growth quality and margin durability are improving faster than the headline multiple suggests.

At roughly 14.5x EV/EBITDA and 19.1x price/free cash flow on the staged FY2025 data, this is not a statistically cheap turnaround if growth falls back to ordinary medical-device levels. It is attractive only if the chronic-care engine can compound faster than peers while reported and adjusted earnings converge.

What I'd Tell a Young Analyst

Watch whether Convatec can turn product launches into repeat usage without paying for growth through reimbursement leakage, quality problems, or undisciplined capex.

The lazy view is "defensive medical devices." The sharper view is that Convatec is a daily-use chronic-care platform with practical switching friction, still proving it can execute like the best peer. Follow new patient starts in ostomy, Convatec-manufactured mix in continence, customer and therapy diversification in infusion, and reimbursement outcomes in wound care; those will tell you more about intrinsic value than a one-year P/E screen.